As a result, the stereotypical kinetics of the first irAEs (skin irAEs between 3–7 weeks, pulmonary irAEs between 10–16 weeks, hepatitis between 6–15 weeks, colitis between 4–10 weeks, and endocrinopathies after 6 weeks for anti-PD-(L)1) [27] may be related to the activation and amplification of the preexisting autoimmune cells, which may differ depending on the type of antigen and the affinity of the selected T cell receptor (TCR), particularly to genetic polymorphisms and especially for PD-1 and PDL-1. This evidence concerns the gene PDCD1 and neoplasm.